JP2022518526A - カルバメート誘導体およびその使用 - Google Patents
カルバメート誘導体およびその使用 Download PDFInfo
- Publication number
- JP2022518526A JP2022518526A JP2021543144A JP2021543144A JP2022518526A JP 2022518526 A JP2022518526 A JP 2022518526A JP 2021543144 A JP2021543144 A JP 2021543144A JP 2021543144 A JP2021543144 A JP 2021543144A JP 2022518526 A JP2022518526 A JP 2022518526A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- compound according
- alkoxy
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 **C(C(O*)=O)OC(N(*)C(*)*)=O Chemical compound **C(C(O*)=O)OC(N(*)C(*)*)=O 0.000 description 68
- RILVNLMOTMFTMQ-UHFFFAOYSA-N CCc1ncccn1 Chemical compound CCc1ncccn1 RILVNLMOTMFTMQ-UHFFFAOYSA-N 0.000 description 2
- AAFFTDXPYADISO-UHFFFAOYSA-N C1CC#CCC1 Chemical compound C1CC#CCC1 AAFFTDXPYADISO-UHFFFAOYSA-N 0.000 description 1
- OVYGGPIHXOMKJF-UHFFFAOYSA-N CC(C)(C)C(COC(CCC(OCC(C(C(C1O)O)O)OC1O)=O)=O)C(C(O)=C1O)OC1O Chemical compound CC(C)(C)C(COC(CCC(OCC(C(C(C1O)O)O)OC1O)=O)=O)C(C(O)=C1O)OC1O OVYGGPIHXOMKJF-UHFFFAOYSA-N 0.000 description 1
- RWLDEANYDIXQFR-UHFFFAOYSA-N CC(C)(C)C[n]1ncnc1 Chemical compound CC(C)(C)C[n]1ncnc1 RWLDEANYDIXQFR-UHFFFAOYSA-N 0.000 description 1
- NSZHPLABMPZYRD-UHFFFAOYSA-N CC(C)(C)S(NC(C=C)c1ccc(C(F)(F)F)nc1)O Chemical compound CC(C)(C)S(NC(C=C)c1ccc(C(F)(F)F)nc1)O NSZHPLABMPZYRD-UHFFFAOYSA-N 0.000 description 1
- QHTSIXVQRRGJJX-UHFFFAOYSA-N CC(C)(C)c1ccc(C(F)(F)F)c(F)c1 Chemical compound CC(C)(C)c1ccc(C(F)(F)F)c(F)c1 QHTSIXVQRRGJJX-UHFFFAOYSA-N 0.000 description 1
- UYZATGCMGXLIOB-UHFFFAOYSA-N CC(C)(C)c1cnc(C(F)(F)F)cn1 Chemical compound CC(C)(C)c1cnc(C(F)(F)F)cn1 UYZATGCMGXLIOB-UHFFFAOYSA-N 0.000 description 1
- QORASYMIGQPSFV-UHFFFAOYSA-N CC(C)OC(C(CC1=NC=CC(C)N1)OC(NC(C)c1ccc(C(F)(F)F)cc1OC)=O)=O Chemical compound CC(C)OC(C(CC1=NC=CC(C)N1)OC(NC(C)c1ccc(C(F)(F)F)cc1OC)=O)=O QORASYMIGQPSFV-UHFFFAOYSA-N 0.000 description 1
- QUYWNSQKNHEZLO-KNVGNIICSA-N CC(C)OC(C(Cc1ncccn1)OC(N[C@@H](C)c(cc1)ccc1Cl)=O)=O Chemical compound CC(C)OC(C(Cc1ncccn1)OC(N[C@@H](C)c(cc1)ccc1Cl)=O)=O QUYWNSQKNHEZLO-KNVGNIICSA-N 0.000 description 1
- BPOROXFMOYOJEE-MAUKXSAKSA-N CC(C)OC([C@@H](C[n]1ncnc1)OC(N[C@@H](C)c1ccc(C(C)(C)C)cc1)=O)=O Chemical compound CC(C)OC([C@@H](C[n]1ncnc1)OC(N[C@@H](C)c1ccc(C(C)(C)C)cc1)=O)=O BPOROXFMOYOJEE-MAUKXSAKSA-N 0.000 description 1
- CVLGDRIRUDVWJE-WMZHIEFXSA-N CC(C)OC([C@@H](C[n]1ncnc1)OC(N[C@@H](C)c1ccc(CCc2ccccc2)cc1)=O)=O Chemical compound CC(C)OC([C@@H](C[n]1ncnc1)OC(N[C@@H](C)c1ccc(CCc2ccccc2)cc1)=O)=O CVLGDRIRUDVWJE-WMZHIEFXSA-N 0.000 description 1
- BGNWXRJWDQHCRB-UHFFFAOYSA-N CC(C)c1ncccn1 Chemical compound CC(C)c1ncccn1 BGNWXRJWDQHCRB-UHFFFAOYSA-N 0.000 description 1
- WYECURVXVYPVAT-UHFFFAOYSA-N CC(c(cc1)ccc1Br)=O Chemical compound CC(c(cc1)ccc1Br)=O WYECURVXVYPVAT-UHFFFAOYSA-N 0.000 description 1
- OEGFFZSWJJTGOU-UHFFFAOYSA-N CC(c1ccc(C(F)(F)F)cc1OC)=O Chemical compound CC(c1ccc(C(F)(F)F)cc1OC)=O OEGFFZSWJJTGOU-UHFFFAOYSA-N 0.000 description 1
- SAPFYSOLOKMUGD-UHFFFAOYSA-N CC(c1ccc(C(F)(F)F)cc1OC)N Chemical compound CC(c1ccc(C(F)(F)F)cc1OC)N SAPFYSOLOKMUGD-UHFFFAOYSA-N 0.000 description 1
- IYHOKSRAXUZRSV-UHFFFAOYSA-N CC(c1ccc(C(F)(F)F)cc1OC)O Chemical compound CC(c1ccc(C(F)(F)F)cc1OC)O IYHOKSRAXUZRSV-UHFFFAOYSA-N 0.000 description 1
- NAUKVLRFGMDIAN-UHFFFAOYSA-N CC(c1ccc(C(F)(F)F)nc1)=O Chemical compound CC(c1ccc(C(F)(F)F)nc1)=O NAUKVLRFGMDIAN-UHFFFAOYSA-N 0.000 description 1
- HIPAIKSXHJHWJX-UHFFFAOYSA-N CCC(C(C(C1O)O)O)OC1O Chemical compound CCC(C(C(C1O)O)O)OC1O HIPAIKSXHJHWJX-UHFFFAOYSA-N 0.000 description 1
- SMRKNBFOFPFACM-RNODOKPDSA-N CCC(C)(C)[S@](N[C@@H](C)c1ccc(C(C)(C)C)cc1)=O Chemical compound CCC(C)(C)[S@](N[C@@H](C)c1ccc(C(C)(C)C)cc1)=O SMRKNBFOFPFACM-RNODOKPDSA-N 0.000 description 1
- FLNMQGISZVYIIK-UHFFFAOYSA-N CC[n]1nccc1 Chemical compound CC[n]1nccc1 FLNMQGISZVYIIK-UHFFFAOYSA-N 0.000 description 1
- KPQLBSBYDIEPQJ-UHFFFAOYSA-N CNc(cc1)cc(S)c1S Chemical compound CNc(cc1)cc(S)c1S KPQLBSBYDIEPQJ-UHFFFAOYSA-N 0.000 description 1
- KKESHHUPAFNMPH-UHFFFAOYSA-N COc1cc(C(F)(F)F)ccc1C=O Chemical compound COc1cc(C(F)(F)F)ccc1C=O KKESHHUPAFNMPH-UHFFFAOYSA-N 0.000 description 1
- PCEWQKPGPCLIEG-UHFFFAOYSA-N CSc(nc1)cnc1S Chemical compound CSc(nc1)cnc1S PCEWQKPGPCLIEG-UHFFFAOYSA-N 0.000 description 1
- PINPOEWMCLFRRB-LURJTMIESA-N C[C@@H](c(cc1)ccc1Cl)N Chemical compound C[C@@H](c(cc1)ccc1Cl)N PINPOEWMCLFRRB-LURJTMIESA-N 0.000 description 1
- MDGZWQDRYKKTOB-ZETCQYMHSA-N C[C@@H](c(cc1)ccc1Cl)N=C=O Chemical compound C[C@@H](c(cc1)ccc1Cl)N=C=O MDGZWQDRYKKTOB-ZETCQYMHSA-N 0.000 description 1
- DMQWKPANEILIOY-JTQLQIEISA-N C[C@@H](c1ccc(C(C)(C)C)cc1)N=C=O Chemical compound C[C@@H](c1ccc(C(C)(C)C)cc1)N=C=O DMQWKPANEILIOY-JTQLQIEISA-N 0.000 description 1
- LFGFRDOHHULTFC-LURJTMIESA-N C[C@@H](c1ccc(C(F)(F)F)nc1)N=C=O Chemical compound C[C@@H](c1ccc(C(F)(F)F)nc1)N=C=O LFGFRDOHHULTFC-LURJTMIESA-N 0.000 description 1
- CDBNFLYUKPRUIQ-AWEZNQCLSA-N C[C@@H](c1ccc(CCc2ccccc2)cc1)N=C=O Chemical compound C[C@@H](c1ccc(CCc2ccccc2)cc1)N=C=O CDBNFLYUKPRUIQ-AWEZNQCLSA-N 0.000 description 1
- OBFNRKKBUKSOEX-INIZCTEOSA-N C[C@@H](c1ccc(CCc2ccccc2)cc1)NC1CCC1 Chemical compound C[C@@H](c1ccc(CCc2ccccc2)cc1)NC1CCC1 OBFNRKKBUKSOEX-INIZCTEOSA-N 0.000 description 1
- DGJSZPXMMBFSHF-INIZCTEOSA-N C[C@@H](c1ccc(CCc2ccccc2)cc1)NSC(C)(C)C Chemical compound C[C@@H](c1ccc(CCc2ccccc2)cc1)NSC(C)(C)C DGJSZPXMMBFSHF-INIZCTEOSA-N 0.000 description 1
- GXIXSGUDPIONGM-UHFFFAOYSA-N Cc(cc1)ccc1OCC(F)(F)F Chemical compound Cc(cc1)ccc1OCC(F)(F)F GXIXSGUDPIONGM-UHFFFAOYSA-N 0.000 description 1
- IYKXPOCKTZADOH-UHFFFAOYSA-N Cc(cn1)ccc1S Chemical compound Cc(cn1)ccc1S IYKXPOCKTZADOH-UHFFFAOYSA-N 0.000 description 1
- DPBMOEZTWZVXLL-UHFFFAOYSA-N Cc1ccc(C(F)(F)F)cc1Cl Chemical compound Cc1ccc(C(F)(F)F)cc1Cl DPBMOEZTWZVXLL-UHFFFAOYSA-N 0.000 description 1
- WHKKNAFVYPYSSU-UHFFFAOYSA-N Cc1ccc(C(F)(F)F)cc1OC Chemical compound Cc1ccc(C(F)(F)F)cc1OC WHKKNAFVYPYSSU-UHFFFAOYSA-N 0.000 description 1
- HALCBPJUGWBVBU-UHFFFAOYSA-N Cc1ccc(C(F)(F)F)nc1 Chemical compound Cc1ccc(C(F)(F)F)nc1 HALCBPJUGWBVBU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796724P | 2019-01-25 | 2019-01-25 | |
| US62/796,724 | 2019-01-25 | ||
| PCT/EP2020/051836 WO2020152361A1 (en) | 2019-01-25 | 2020-01-24 | Carbamate derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518526A true JP2022518526A (ja) | 2022-03-15 |
| JP2022518526A5 JP2022518526A5 (https=) | 2023-01-31 |
| JPWO2020152361A5 JPWO2020152361A5 (https=) | 2023-01-31 |
Family
ID=69375331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543144A Pending JP2022518526A (ja) | 2019-01-25 | 2020-01-24 | カルバメート誘導体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220098159A1 (https=) |
| EP (1) | EP3914351A1 (https=) |
| JP (1) | JP2022518526A (https=) |
| KR (1) | KR20210131329A (https=) |
| CN (1) | CN113660983A (https=) |
| AU (1) | AU2020211361A1 (https=) |
| BR (1) | BR112021014389A2 (https=) |
| CA (1) | CA3126495A1 (https=) |
| EA (1) | EA202192057A1 (https=) |
| IL (1) | IL284843A (https=) |
| MX (1) | MX2021008930A (https=) |
| SG (1) | SG11202107653RA (https=) |
| WO (1) | WO2020152361A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| GB201712282D0 (en) | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999012534A1 (en) * | 1997-09-10 | 1999-03-18 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
| JP2004515538A (ja) * | 2000-12-16 | 2004-05-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | カルボキサミド誘導体並びに血栓塞栓性疾患および腫瘍の処置におけるこれらの使用 |
| JP2018510207A (ja) * | 2015-02-16 | 2018-04-12 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| WO2018167468A1 (en) * | 2017-03-13 | 2018-09-20 | NodThera Limited | Chemical compounds |
| WO2018225018A1 (en) * | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| FI921595A7 (fi) * | 1991-04-17 | 1992-10-18 | American Home Prod | Rapamysiinikarbamaatteja |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US20020002200A1 (en) * | 2000-02-04 | 2002-01-03 | Bishwagit Nag | Novel diphenylethylene compounds |
| WO2017035413A2 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders |
| JP2019512009A (ja) * | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
| RU2720203C1 (ru) * | 2017-01-20 | 2020-04-27 | Пфайзер Инк. | 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl |
| GB201712282D0 (en) | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
-
2020
- 2020-01-24 BR BR112021014389-0A patent/BR112021014389A2/pt not_active Application Discontinuation
- 2020-01-24 KR KR1020217025978A patent/KR20210131329A/ko not_active Abandoned
- 2020-01-24 JP JP2021543144A patent/JP2022518526A/ja active Pending
- 2020-01-24 EA EA202192057A patent/EA202192057A1/ru unknown
- 2020-01-24 WO PCT/EP2020/051836 patent/WO2020152361A1/en not_active Ceased
- 2020-01-24 US US17/425,461 patent/US20220098159A1/en not_active Abandoned
- 2020-01-24 SG SG11202107653RA patent/SG11202107653RA/en unknown
- 2020-01-24 CA CA3126495A patent/CA3126495A1/en active Pending
- 2020-01-24 EP EP20702596.6A patent/EP3914351A1/en not_active Withdrawn
- 2020-01-24 CN CN202080024041.8A patent/CN113660983A/zh active Pending
- 2020-01-24 MX MX2021008930A patent/MX2021008930A/es unknown
- 2020-01-24 AU AU2020211361A patent/AU2020211361A1/en not_active Abandoned
-
2021
- 2021-07-14 IL IL284843A patent/IL284843A/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999012534A1 (en) * | 1997-09-10 | 1999-03-18 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
| JP2004515538A (ja) * | 2000-12-16 | 2004-05-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | カルボキサミド誘導体並びに血栓塞栓性疾患および腫瘍の処置におけるこれらの使用 |
| JP2018510207A (ja) * | 2015-02-16 | 2018-04-12 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| WO2018167468A1 (en) * | 2017-03-13 | 2018-09-20 | NodThera Limited | Chemical compounds |
| WO2018225018A1 (en) * | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3914351A1 (en) | 2021-12-01 |
| MX2021008930A (es) | 2021-11-04 |
| SG11202107653RA (en) | 2021-08-30 |
| EA202192057A1 (ru) | 2021-12-23 |
| AU2020211361A1 (en) | 2021-08-19 |
| KR20210131329A (ko) | 2021-11-02 |
| CA3126495A1 (en) | 2020-07-30 |
| US20220098159A1 (en) | 2022-03-31 |
| WO2020152361A1 (en) | 2020-07-30 |
| IL284843A (en) | 2021-08-31 |
| CN113660983A (zh) | 2021-11-16 |
| BR112021014389A2 (pt) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7357602B2 (ja) | 選択的ｎｌｒｐ３インフラマソーム阻害剤 | |
| JP7339959B2 (ja) | Ｎｌｒｐ３インフラマソーム調節剤としてのスルホニル尿素誘導体 | |
| EP3596052B1 (en) | Chemical compounds | |
| US20230083495A1 (en) | Sulfonylurea derivatives and uses thereof | |
| US12054461B2 (en) | Sulfonylurea derivatives and uses thereof | |
| WO2020157069A1 (en) | Amino heterocyclic compounds and uses thereof | |
| JP2022518526A (ja) | カルバメート誘導体およびその使用 | |
| US20220267300A1 (en) | Sulfonamide derivatives and uses thereof | |
| US20250115558A1 (en) | Pyridazine derivatives and related uses | |
| HK40031620B (en) | Selective inhibitors of nlrp3 inflammasome | |
| HK40021786B (en) | Chemical compounds | |
| HK40021786A (en) | Chemical compounds | |
| HK40032693B (zh) | Nlrp3炎性体的选择性抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230120 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230120 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230519 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231218 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231219 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240708 |